These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31029154)

  • 21. Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis.
    Satoi S; Fujii T; Yanagimoto H; Motoi F; Kurata M; Takahara N; Yamada S; Yamamoto T; Mizuma M; Honda G; Isayama H; Unno M; Kodera Y; Ishigami H; Kon M
    Ann Surg; 2017 Feb; 265(2):397-401. PubMed ID: 28059968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
    Kawamoto Y; Komatsu Y; Yuki S; Sawada K; Muranaka T; Harada K; Nakatsumi H; Fukushima H; Ishiguro A; Dazai M; Hatanaka K; Nakamura M; Iwanaga I; Uebayashi M; Sogabe S; Kobayashi Y; Miyagishima T; Ono K; Sakamoto N; Sakata Y
    BMC Cancer; 2017 Dec; 17(1):837. PubMed ID: 29221445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
    Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer.
    van 't Land FR; Willemsen M; Bezemer K; van der Burg SH; van den Bosch TPP; Doukas M; Fellah A; Kolijn PM; Langerak AW; Moskie M; van der Oost E; Rozendaal NEM; Baart SJ; Aerts JGJV; van Eijck CHJ
    J Clin Oncol; 2024 Sep; 42(26):3083-3093. PubMed ID: 38950309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-BT trial).
    Okusaka T; Ueno M; Sato T; Heike Y
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):314-8. PubMed ID: 22273718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.
    Kajihara M; Takakura K; Kanai T; Ito Z; Matsumoto Y; Shimodaira S; Okamoto M; Ohkusa T; Koido S
    World J Gastroenterol; 2016 May; 22(18):4446-58. PubMed ID: 27182156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.
    Lutz E; Yeo CJ; Lillemoe KD; Biedrzycki B; Kobrin B; Herman J; Sugar E; Piantadosi S; Cameron JL; Solt S; Onners B; Tartakovsky I; Choi M; Sharma R; Illei PB; Hruban RH; Abrams RA; Le D; Jaffee E; Laheru D
    Ann Surg; 2011 Feb; 253(2):328-35. PubMed ID: 21217520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.
    Kaida M; Morita-Hoshi Y; Soeda A; Wakeda T; Yamaki Y; Kojima Y; Ueno H; Kondo S; Morizane C; Ikeda M; Okusaka T; Takaue Y; Heike Y
    J Immunother; 2011 Jan; 34(1):92-9. PubMed ID: 21150717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy.
    Saeki H; Emi Y; Oki E; Tokunaga S; Kakeji Y; Akagi Y; Baba H; Baba E; Maehara Y;
    BMC Cancer; 2018 Jan; 18(1):57. PubMed ID: 29310611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
    Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
    Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
    Front Immunol; 2021; 12():691605. PubMed ID: 34484187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy for pancreatic cancer.
    Springfeld C; Jäger D; Büchler MW; Strobel O; Hackert T; Palmer DH; Neoptolemos JP
    Presse Med; 2019 Mar; 48(3 Pt 2):e159-e174. PubMed ID: 30879894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies.
    Yang J; Shangguan J; Eresen A; Li Y; Wang J; Zhang Z
    Pathol Res Pract; 2019 Dec; 215(12):152691. PubMed ID: 31676092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma.
    Naito S; Tsukamoto T; Usami M; Fujimoto H; Akaza H
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1065-70. PubMed ID: 20157711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial.
    Wang Q; Tong F; Qiao L; Qi L; Sun Y; Zhu Y; Ni J; Liu J; Kong W; Liu B; Du J
    Cancer Immunol Immunother; 2024 Aug; 73(10):201. PubMed ID: 39105880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.
    Balachandran VP; Beatty GL; Dougan SK
    Gastroenterology; 2019 May; 156(7):2056-2072. PubMed ID: 30660727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
    Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y;
    Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.
    Ikeda M; Ioka T; Ito Y; Yonemoto N; Nagase M; Yamao K; Miyakawa H; Ishii H; Furuse J; Sato K; Sato T; Okusaka T
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):163-9. PubMed ID: 22677367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
    Koga T; Sato S; Miyamoto J; Hagimori N; Kawazoe Y; Arinaga K; Fukushima C; Yamamoto H; Kawakami A
    Trials; 2018 Dec; 19(1):715. PubMed ID: 30594222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.